Quantitative Proteomic Profile of Caribbean Hispanics with Resistance to Clopidogrel

Abstract

The resistance to clopidogrel increases the risk of ischemic events in adults with coronary artery disease. This resistance varies with ethnicity, genetic, and many other clinical variables. Proteomic data from studies on Caribbean Hispanic (CH) patients treated with clopidogrel that have developed resistance has not yet been conducted. Thus, this is the first study performed on patients from the Caribbean region that also uses a cutting‐edge proteomic approach to a Precision Medicine application. A 10‐plex tandem mass tag labeling quantitative proteomic analysis was performed on plasma proteins isolated from CH patients treated with clopidogrel. Plasma samples from 6 patients were divided into two groups: non‐responder (High P2Y12 reaction units (PRU) ≥230) and responder (Low PRU <230). Both groups were compared with cardiovascular patients under other treatments. A total of 201 proteins were identified in the plasma. For the non‐responder group, 74 proteins were significantly down‐regulated, and 22 proteins were up‐regulated. Conversely, 55 proteins were significantly down‐regulated, whereas 28 proteins were up‐regulated in the responder group. Bioinformatic analysis showed that 8 of the regulated proteins were associated to the blood coagulation system pathway, and 5 proteins were associated with Intrinsic prothrombin activation pathway. Also, some of the significantly regulated proteins participate in two interaction networks associated with Acute coronary syndrome and Acute myocardial infarction. The proteomic analysis demonstrates differences in protein abundance regarding clopidogrel responses. These findings are expected to provide preliminary evidence on early expression of novel biomarkers in CH cardiovascular patients with resistance to clopidogrel.Support or Funding InformationThis study was supported by grant # 2U54 MD007600‐31 and Research Supplement to Promote Diversity in Health‐Related Research from NIMHD, NIH (CCRHD‐RCMI Program at UPR MSC).